Organogenesis Holdings will release Q4 and fiscal year 2024 financial results on February 27, followed by a conference call.
Quiver AI Summary
Organogenesis Holdings Inc. announced that it will report its fourth quarter and fiscal year 2024 financial results after market close on February 27, 2025. Following the announcement, management will hold a conference call at 5:00 p.m. Eastern Time to discuss the results and provide a corporate update, including a question and answer session. Interested participants can join via a live webcast or teleconference, with the webcast also available for approximately one year on the company's website. Organogenesis specializes in regenerative medicine, offering innovative products for advanced wound care and surgical and sports medicine.
Potential Positives
- Organogenesis Holdings Inc. is set to announce its fourth quarter and fiscal year 2024 financial results, potentially indicating growth or success in their markets.
- The management will host a conference call to discuss the financial results and provide a corporate update, demonstrating transparency and engagement with investors.
- The opportunity for a live Q&A session suggests the company is open to addressing investor concerns and fostering communication.
- The archived webcast will make the information accessible for future reference, enhancing stakeholder engagement.
Potential Negatives
- Failure to disclose preliminary financial results or any expectations leading into the earnings release may lead to concerns about the company's financial health.
- Scheduling a conference call after market close could suggest that there may be disappointing results that the company wants to address immediately rather than during market hours.
FAQ
When will Organogenesis report its fourth quarter and fiscal year 2024 results?
Organogenesis will report its financial results on February 27th, after the market closes.
How can I participate in the Organogenesis conference call?
Participants can access the live conference call via the webcast or teleconference options provided in the announcement.
What time is the Organogenesis conference call scheduled?
The conference call will begin at 5:00 p.m. Eastern Time on February 27th.
Where can I find Organogenesis' archived webcast of the conference call?
The archived webcast will be available on the company’s website for approximately one year.
What markets does Organogenesis focus on?
Organogenesis is focused on advanced wound care and surgical and sports medicine markets.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ORGO Insider Trading Activity
$ORGO insiders have traded $ORGO stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ORGO stock by insiders over the last 6 months:
- GARY S. GILLHEENEY (President and CEO) has made 0 purchases and 7 sales selling 380,000 shares for an estimated $1,358,145.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ORGO Hedge Fund Activity
We have seen 55 institutional investors add shares of $ORGO stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEUTSCHE BANK AG\ added 2,339,633 shares (+93.4%) to their portfolio in Q3 2024, for an estimated $6,691,350
- ASSENAGON ASSET MANAGEMENT S.A. added 1,035,120 shares (+54.0%) to their portfolio in Q4 2024, for an estimated $3,312,384
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 649,900 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,858,714
- NUVEEN ASSET MANAGEMENT, LLC added 592,256 shares (+325.2%) to their portfolio in Q3 2024, for an estimated $1,693,852
- AQR CAPITAL MANAGEMENT LLC added 441,846 shares (+19.5%) to their portfolio in Q3 2024, for an estimated $1,263,679
- MORGAN STANLEY added 393,675 shares (+3.4%) to their portfolio in Q3 2024, for an estimated $1,125,910
- SOLEUS CAPITAL MANAGEMENT, L.P. added 320,922 shares (+2.8%) to their portfolio in Q3 2024, for an estimated $917,836
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th.
Management will host a conference call at 5:00 p.m. Eastern Time on February 27th to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here , or access the teleconference here . The live webcast can also be accessed via the company’s website at investors.organogenesis.com . The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit
www.organogenesis.com
.